Core Insights - The Hong Kong Innovative Drug 50 ETF (513780) experienced a 1.48% increase in value on August 21, with a trading volume of 582 million yuan [1] - The fund's shares increased by 13 million to a total of 1.315 billion shares, with a notable increase of 616 million shares over the past 20 trading days [1] - The latest net asset value of the fund is calculated at 2.518 billion yuan [1] - The fund's performance benchmark is the CSI Hong Kong Stock Connect Innovative Drug Index, adjusted for valuation exchange rates [1] - The fund is managed by Invesco Great Wall Fund Management Co., Ltd., with fund managers Jin Huang and Zhang Xiaonan [1] - Since its establishment on October 16, 2024, the fund has achieved a return of 91.49%, with a monthly return of 10.67% [1]
8月21日港股创新药50ETF（513780）份额增加1300.00万份，最新份额13.15亿份，最新规模25.18亿元
Xin Lang Cai Jing·2025-08-22 01:12